Jump to content
Main menu
Main menu
move to sidebar
hide
Navigation
Main Page
My Profile
My Assessments
My Life Story
Administer Assessments
Med Classes
Problems
Recent changes
Feature requests
Pharmacopedia
Search
Search
Appearance
Create account
Log in
Personal tools
Create account
Log in
Drilldown: Medicines
English
Tools
Tools
move to sidebar
hide
Actions
General
Printable version
Appearance
move to sidebar
hide
Pharmacopedia
Browse
Categories
Log in
Pharmacopedia is being built in public. Pages may be incomplete.
About this site
×
Nav
Pharmacopedia
×
Main
Main page
Medicines A–Z
Categories
Recent changes
My account
Log in
Help
About
Special pages
Feature requests
Choose a table:
Medicines (732)
Medicines
> preparations:
Tablets 12.5, 25 mg; chewable tablets 25 mg
&
halflife:
~6 hours'"`UNIQ--ref-00000018-QINU`"'
Use the filters below to narrow your results.
generic:
Meclizine (1)
brand:
Antivert (Rx), Bonine (OTC), Dramamine Less Drowsy (OTC) (1)
classes:
[[:Category:Antiemetics|Antiemetic]] (1)
·
[[:Category:Antihistamines|First-generation antihistamine (piperazine)]] (1)
·
[[:Category:Antivertigo medicines|Antivertigo medicine]] (1)
mechanism:
'"`UNIQ--vote-00000013-QINU`"' Anticholinergic burden (dry mouth, blurred vision, urinary retention, cognitive effects) is the principal adverse-event concern and the basis for Beers-list cautions in elderly patients'"`UNIQ--ref-00000014-QINU`"'. (1)
uses:
'"`UNIQ--vote-00000015-QINU`"', '"`UNIQ--vote-00000016-QINU`"', '"`UNIQ--vote-00000017-QINU`"' (1)
starting dose:
Motion sickness: 25-50 mg PO 1 hour before travel, repeat every 24 hours as needed. Vertigo: 25-100 mg/day divided (1)
preparations:
(Click arrow to add another value)
None
·
10 mg, 20 mg, 40 mg, 80 mg tablets
·
2.5, 5, 10, 20 mg tabs
·
5 mg, 10 mg tablets
·
5, 10 mg tablets
·
5, 10, 20, 40 mg tablets
·
0.005% ophthalmic solution (50 mcg/mL); typical 2.5 mL bottle
·
0.01%, 0.03% ophthalmic solution
·
0.025%, 0.035% ophthalmic solutions
·
0.1% (Patanol), 0.2% (Pataday once-daily original), 0.7% (Pataday 24-hour) ophthalmic solutions; 0.6% nasal spray
·
0.1%, 0.15% intranasal spray; 0.05% ophthalmic solution; combination Dymista (azelastine 0.137 mg + fluticasone 50 mcg/spray)
·
0.1%, 0.15%, 0.2% ophthalmic solutions; 0.33% topical gel; combinations with timolol (Combigan) and brinzolamide (Simbrinza)
·
0.225%, 0.45%, 0.9%, 3%, 5% IV solutions; 0.9% nasal spray; 3% and 7% nebulizer solutions; oral tablets (1 g)
·
0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate
·
0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg tablets
·
0.25, 0.5 mcg oral capsules; 1 mcg/mL oral solution; 1 mcg/mL IV; 3 mcg/g topical ointment
·
0.35 mg POP tablets; 5 mg tablets (Aygestin); component of COCs and combination HRT
·
0.4 mg capsules
·
0.4, 0.8, 1 mg OTC; 1 mg Rx; 5 mg/mL injection
·
0.5 g, 1 g capsules
Other values:
0.5 g/mL oral solution
0.5 mg capsules
0.5% (Carac), 1% (Fluoroplex), 5% (Efudex) topical creams/solutions; 50 mg/mL IV
0.5, 0.75, 1, 1.5, 2, 4, 6 mg tablets; oral solution; 4, 10, 20, 100 mg/mL IV; intravitreal implant (Ozurdex)
0.5, 1, 2 mg tablets; 0.25 mg/mL IV
0.6 mg tablets; 0.6 mg/5 mL solution; 0.5 mg tablets (Lodoco)
0.6 mg/5 mL oral solution; Celestone Soluspan 6 mg/mL IM/IA (mix of sodium phosphate + acetate); 0.05% and 0.1% topical cream/ointment/lotion/foam (various salts); augmented betamethasone 0.05% (super-high potency)
0.77% topical cream, lotion, suspension; 1% shampoo; 8% nail lacquer (Penlac)
1 g soft gelatin capsules containing ~465 mg EPA + ~375 mg DHA as ethyl esters
1 g tablets; 1 g/10 mL suspension
1 mg tablets
1 mg, 2 mg, 4 mg tablets
1 mg, 5 mg tablets
1% (OTC), 2% (Rx) shampoo; 2% cream; 2% gel; 200 mg oral tablet (rarely used now)
1% topical cream, lotion, solution; 1%, 2% vaginal cream; 100, 200, 500 mg vaginal tablets; 10 mg oral troches; combination with betamethasone (Lotrisone, Rx)
1, 2, 2.5, 3, 4, 5, 6, 7.5, 10 mg tablets (color-coded by strength)
1, 2, 4, 8 mg IR tablets; 4, 8 mg XL tablets
1, 2, 5 mg caps
1, 2, 5, 10 mg capsules and tablets
1, 2.5, 5, 10, 20, 50 mg tablets; 5 mg/5 mL syrup; 5 mg/mL concentrate
1.25, 2.5, 5, 10 mg capsules
1.5 mg, 3 mg, 4.5 mg, 6 mg capsules
10 g/15 mL solution (Constulose); 10 g, 20 g powder packets (Kristalose)
10 mg tablet; also as fixed-dose combinations with simvastatin (Vytorin) and atorvastatin (Liptruzet, withdrawn US 2015 but generics exist)
10 mg tablets; 4 mg, 5 mg chewables; 4 mg granules
10 mg tablets; 5 mg ODT and chewables; 1 mg/mL oral syrup; combo Claritin-D (with pseudoephedrine, behind-counter)
10 mg, 20 mg, 40 mg caps
10 mg, 20 mg, 40 mg tablets
10 mg, 20 mg, 40 mg tablets; chewables; 40 mg/5 mL oral suspension; 10 mg/mL IV
10 mg, 25 mg tablets
10 mg, 34 mg capsules/tablets
10 mg/spray nasal solution
10, 20 mg IR capsules; 30, 60, 90 mg ER tablets
10, 20 mg tablets/capsules; 10 mg/5 mL syrup; 10 mg/mL IM injection
10, 20, 40 mg delayed-release capsules and tablets; 2 mg/mL oral suspension; immediate-release combo with sodium bicarbonate (Zegerid)
10, 20, 40 mg tablets; 20, 40, 60 mg ER tablets
10, 20, 40, 60, 80 mg tabs; 60/80/120/160 mg ER caps; 1 mg/mL IV
10, 25, 50, 100 mg tablets; 20 mg/mL IV
100 U/mL (FlexTouch pen) and 200 U/mL (FlexTouch pen, higher-dose convenience)
100 U/mL (Humalog, Admelog, Lyumjev) vials, pens, cartridges; 200 U/mL Humalog KwikPen
100 U/mL (Lantus, Basaglar, Semglee) vials and pens; 300 U/mL (Toujeo) pens
100 U/mL (NovoLog, Fiasp) vials, pens, cartridges
100 U/mL FlexTouch pen, vial
100 mg tabs
100 mg, 150 mg, 200 mg extended-release capsules (can be sprinkled on food)
100 mg, 300 mg tablets; IV 500 mg vial
100 mg/20 mL vial, single-use
100 mg/mL vial for IV infusion
100, 150, 200 mg liquid-filled capsules ("perles")
100, 200, 400 IU softgels and capsules; many proprietary OTC blends; combined formulations (AREDS-2)
100, 200, 400 mg IR tablets; 600 mg, 1200 mg Mucinex ER tablets; many liquid formulations and combination products with dextromethorphan, pseudoephedrine, antihistamines
100, 200, 400 mg tablets; 50 mg/mL IV (with polysorbate 80 in older formulations causing hypotension); 1.5 mg/mL Nexterone IV (PVC-free, lower hypotension risk)
100, 250, 500, 1000 mg tablets, chewables, gummies, effervescent; IV (specialty)
100, 250, 500, 1000, 5000 mcg tablets (OTC and Rx); 1000 mcg/mL injection; intranasal spray; sublingual
100,000 units/mL oral suspension; 500,000 unit tablets; 100,000 units/g cream, ointment, powder; vaginal tablets
12.5 mg capsules; 12.5, 25, 50 mg tablets
120 mg/mL prefilled syringe or autoinjector
125, 250, 500 mg delayed-release tablets (Depakote); 250, 500 mg ER tablets (Depakote ER); 125, 250 mg sprinkle capsules; 250 mg/5 mL syrup; 500 mg IV (Depacon)
125, 250, 500 mg tablets; 125 mg/5 mL, 250 mg/5 mL suspension; 750 mg, 1.5 g IV vials
140 mg/mL single-use prefilled syringe and SureClick autoinjector; Pushtronex 420 mg/3.5 mL on-body infusor
15 mg, 25 mg, 50 mg tablets
15, 30, 37.5 mg capsules/tablets; 8 mg Lomaira
15, 30, 45 mg tablets
15, 30, 60, 90, 120, 180, 240, 300 mg tablets (1/4 to 5 grains; 1 grain = 60 mg)
17 g (OTC) and 14 g (Rx) powder packets; 238, 510, 527 g bottles; PEG-electrolyte preparations 4 L (GoLYTELY, NuLYTELY)
18 mcg HandiHaler capsules; 2.5 mcg/actuation Respimat solution inhaler (1.25 mcg/actuation for asthma indication)
2 mg capsules and tablets; 1 mg/5 mL oral solution; combined with simethicone (Imodium Multi-Symptom)
2% ointment; 2% cream; 2% nasal ointment (Bactroban Nasal)
2% ophthalmic solution (Trusopt); 2%/0.5% fixed combination with timolol (Cosopt, Cosopt PF)
2%, 4% wash; 2% CHG/70% IPA applicators (ChloraPrep); 0.12%, 0.2% oral rinse; impregnated catheter dressings
2, 4, 8, 16, 32 mg oral tablets; 40, 125, 500, 1000 mg IV vials; Depo-Medrol 20, 40, 80 mg/mL IM depot
2.5 mg tablets; 10-50 mg/mL injection; pre-filled subcutaneous autoinjectors (Otrexup, Rasuvo); 2.5 mg/mL oral solution (Xatmep)
2.5 mg, 5 mg tablets
2.5, 10, 15, 20 mg tablets
2.5, 5, 10 mg oral tablets; Depo-Provera 150 mg/mL IM; Depo-SubQ Provera 104 mg/0.65 mL
2.5, 5, 10 mg tablets; 1 mg/mL oral suspension
2.5, 5, 10, 20 mg tablets; 1 mg/mL oral solution (Epaned); 1.25 mg/mL IV (enalaprilat)
2.5, 5, 10, 20 mg tabs (Levitra); 10 mg ODT (Staxyn)
2.5, 5, 10, 20, 30, 40 mg tablets; 1 mg/mL oral solution
20 mg dextromethorphan HBr / 10 mg quinidine sulfate capsules
20 mg, 25 mg, 30 mg capsules
20 mg, 40 mg delayed-release tablets; 40 mg IV vial; oral suspension 40 mg/packet
20, 40 mg delayed-release capsules; 2.5, 5, 10, 20, 40 mg oral suspension packets; 20, 40 mg IV
20, 40, 80 mg tablets
20, 40, 80 mg tablets; 10 mg/mL oral solution; 10 mg/mL IV
200 mg tablets; 100 mg/5 mL suspension
200 mg/2 mL, 500 mg/5 mL vials for IV infusion
200, 300, 400 mg tablets (mostly generic now); 0.3% ophthalmic solution; 0.3% otic solution
200, 300, 400, 500 mg IR tablets/capsules; 400, 500, 600 mg ER tablets
200, 400, 800 mg tablets; 200 mg capsules; 200 mg/5 mL suspension; 500, 1000 mg IV vials; 5% cream and ointment (topical)
225 mg/1.5 mL prefilled syringe or autoinjector
25 mg, 50 mg tablets
25 mg, 50 mg, 100 mg tablets
25 mg, 50 mg, 100 mg tablets; 25 mg/5 mL oral suspension (CaroSpir)
25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL
25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg immediate-release tablets; 50 mg, 150 mg, 200 mg, 300 mg, 400 mg extended-release tablets (Seroquel XR)
25 mg/5 mL suspension; 25, 50, 100 mg capsules (Macrodantin); 100 mg Macrobid capsule
25, 50 mg ER tablets; 8 mg/mL granules for oral suspension (Myrbetriq Granules, pediatric)
25, 50, 100 mg tablets; combination tablets with metformin
25, 50, 100 mg tabs (Viagra); 20 mg tabs and 10 mg/mL oral suspension (Revatio)
25, 50, 100, 250, 400 mg tablets; OTC
25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200, 300 mcg tablets; oral capsule and IV/IM also available
250 mg tablets; 1% topical cream, gel, spray; granules (pediatric)
250 mg, 500 mg capsules; 500 mg, 875 mg tablets; 125, 200, 250, 400 mg/5 mL oral suspension; 775 mg ER; 50 mg/mL drops
250 mg, 500 mg tablets; 125 mg/5 mL, 250 mg/5 mL suspension
250 mg, 500 mg, 600 mg tablets; 100, 200 mg/5 mL suspension; 2 g ER suspension (Zmax); 500 mg IV
250 mg, 500 mg, 750 mg capsules; 250 mg/5 mL, 125 mg/5 mL suspension; tablets
250, 500 mg base or stearate tablets; ER tablets; ethyl succinate 200 mg/5 mL suspension; 500 mg, 1 g IV (lactobionate); 2% topical solution/gel; 0.5% ophthalmic ointment
250, 500 mg tablets; 750 mg ER; 500 mg/100 mL IV; 0.75-1% topical gel/cream; 0.75% vaginal gel; suppository
250, 500, 1000 mL IV bags. Composition per liter: Na+ 130 mEq, K+ 4 mEq, Ca2+ 3 mEq, Cl- 109 mEq, lactate 28 mEq
250, 500, 750 mg IR tablets; 500, 1000 mg ER tablets (XR); 250, 500 mg/5 mL oral suspension; 200, 400 mg IV; 0.3% ophthalmic solution and ointment; 0.2% otic
250, 500, 750 mg tablets; 25 mg/mL oral solution; 25 mg/mL IV (premix bags 250, 500, 750 mg); 0.5%, 1.5% ophthalmic solutions
28 mg/device (each dose uses 2 devices)
3 mg tablets (Stromectol); 0.5% topical lotion (Sklice); 1% topical cream (Soolantra)
30, 45, 75 mg capsules; 6 mg/mL oral suspension
30, 60, 180 mg tablets; 30 mg ODT; 6 mg/mL oral suspension; all OTC
300 mg capsules; 125, 250 mg/5 mL suspension
325 mg tablets (65 mg elemental Fe); 220 mg/5 mL liquid (44 mg elemental Fe/5 mL); 142 mg/mL drops; OTC and Rx
325, 500, 650 mg tablets; 80, 160 mg chewables; 160 mg/5 mL pediatric liquid; 325 mg suppository; 1000 mg/100 mL IV (Ofirmev); fixed-dose combinations with opioids, decongestants, antihistamines
350 mg/20 mL vial for IV infusion
4 mg, 8 mg, 24 mg tablets; 4 mg, 8 mg orally disintegrating tablets; 4 mg/5 mL oral solution; IV (2 mg/mL)
4% prescription cream/lotion; OTC 2% withdrawn in US (2020 CARES Act); compounded higher strengths available
4.2%, 7.5%, 8.4% IV (1 mEq/mL at 8.4%); 325, 650 mg oral tablets; bulk powder
4.45 mg, 17.8 mg tablets
4.8355 mg oxycodone / 325 mg aspirin tablets
40 mg/0.4 mL or 40 mg/0.8 mL prefilled syringe and autoinjector pen; 10, 20, 80 mg pediatric/induction strengths
40, 80, 160, 320 mg tablets; oral suspension
400 mg tablets; 400 mg/250 mL IV; 0.5% ophthalmic solution
42 mg capsules
5 mg IR tablets; 5, 10, 15 mg ER tablets; 5 mg/5 mL syrup; 3.9 mg/24 h transdermal patch (Oxytrol); 10% topical gel
5 mg enteric-coated tablets; 10 mg rectal suppositories; OTC and Rx
5 mg tablets; 2.5 mg/5 mL oral solution; OTC
5 mg tablets; 5 mg/5 mL, 10 mg/5 mL, 15 mg/5 mL oral solutions (sweetened pediatric); 5 mg/5 mL syrup; ophthalmic 0.12%, 1% suspensions and 1% solution
5 mg tablets; combination with metformin
5 mg, 10 mg immediate-release tablets; 2.5 mg, 5 mg, 10 mg extended-release tablets
5 mg, 10 mg tablets; 5 mg, 10 mg chewables; 1 mg/mL oral syrup; OTC
5 mg, 10 mg, 15 mg, 20 mg tablets
5 mg, 10 mg, 20 mg tablets
5, 10 mg tablets; 5 mg/5 mL solution; 5 mg/mL IV; 15 mg/spray intranasal
5, 10 mg tabs
5, 10, 20 mg oral tablets; 100, 250, 500, 1000 mg IV (Solu-Cortef); 0.5%, 1%, 2.5% topical creams/ointments; rectal foam and enemas
5, 10, 20, 100 mg tablets; 10 mg/mL IV
5, 10, 20, 40, 80 mg tablets; 4 mg/mL oral suspension
5, 10, 35, 40, 70 mg tablets; 70 mg/75 mL oral solution; 70 mg effervescent (Binosto)
5, 20, 40 mg tablets
5, 25, 50 mcg tablets (Cytomel); 10 mcg/mL IV (Triostat)
50 mg, 75 mg, 100 mg, 150 mg tablets and capsules; delayed-release; suspension; IV
50, 100, 150 mg tablets
50, 100, 150, 200 mg tablets; 10, 40 mg/mL oral suspension; 2 mg/mL IV
50, 100, 200 mg tabs
50, 100, 250 mg capsules; 50 mg/5 mL syrup; OTC
50, 100, or 200 unit vials of lyophilized powder for reconstitution
50,000 IU capsules (Rx); 8,000 IU/mL oral solution (Rx); 400-5,000 IU OTC tablets and softgels
50/325/40 mg capsules
50/325/40 mg capsules and tablets; oral solution
500 mg, 1 g tablets
500 mg, 850 mg, 1000 mg IR tablets; 500 mg, 750 mg, 1000 mg ER tablets; 500 mg/5 mL oral solution
500, 750 mg tablets
60, 90 mg tablets
7/10, 14/10, 21/10, 28/10 mg ER capsules (memantine ER / donepezil)
70 mg/mL or 140 mg/mL prefilled autoinjector
72, 145, 290 mcg capsules
75 mg, 150 mg tablets
75 mg, 300 mg tablets
75, 150, 300 mg capsules; 75 mg/5 mL solution; 150 mg/mL IV; 1% topical; 2% vaginal cream
75, 150, 300 mg tablets
8 mg naltrexone / 90 mg bupropion ER tablets (titration-pack design)
8, 10, 20, 25 mEq tablets/capsules (most ER); effervescent and oral solution; IV concentrate (must be diluted)
85 mg sumatriptan / 500 mg naproxen sodium tablets; lower-dose 10/60 mg pediatric (Treximet pediatric)
95 mg (OTC), 99.5 mg, 100 mg, 200 mg tablets
A ''betel quid'': areca nut slice + betel leaf + slaked lime (calcium hydroxide) ± tobacco ± spices, chewed
Acid/base extraction of fresh young grass for tryptamines; combined with an MAOI
Atrovent HFA 17 mcg/actuation MDI; 500 mcg/2.5 mL nebulizer solution; 0.03% and 0.06% intranasal sprays; with albuterol as DuoNeb / Combivent Respimat
Auto-injectors 0.15 mg (Jr/pediatric), 0.3 mg (adult); 1 mg/mL (1:1,000) ampules for IM/SC use; 0.1 mg/mL (1:10,000) for IV use; 2.25% racemic nebulizer
Bark/woody stem decocted with a DMT-source plant (''Psychotria viridis'', ''Diplopterys cabrerana'') to make ayahuasca
Bicillin L-A 600,000; 1.2M; 2.4M U IM; aqueous crystalline (Pfizerpen) 5M, 20M U IV; procaine 600,000 U/mL IM
Bright red seeds, traditionally ingested or smoked. Highly toxic, narrow margin between active and lethal
Byetta pre-filled multi-dose pen: 5 µg / 10 µg per dose'"`UNIQ--ref-000000E5-QINU`"' · Bydureon BCise single-dose autoinjector: 2 mg extended-release microsphere suspension'"`UNIQ--ref-000000E6-QINU`"'
Capsules 10, 18, 25, 40, 60, 80, 100 mg
Capsules 10, 20, 30, 40, 50, 60, 70 mg; chewable tablets 10, 20, 30, 40, 50, 60 mg
Capsules 10, 25, 50, 75 mg; oral solution 10 mg/5 mL
Capsules 10, 25, 50, 75, 100, 150 mg; oral concentrate 10 mg/mL; Silenor tablets 3, 6 mg; topical cream 5% (Prudoxin, Zonalon)
Capsules 100, 300, 400 mg; tablets 600, 800 mg; oral solution 250 mg/5 mL; Gralise ER tablets 300, 600 mg (once-daily); Horizant ER tablets 300, 600 mg (gabapentin enacarbil, an inactive parent compound metabolized to gabapentin in vivo)
Capsules 25, 50 mg; ER capsules 75 mg; oral suspension 25 mg/5 mL; suppositories 50 mg; injection 1 mg/vial (PDA closure)
Capsules 25, 50, 75, 100, 150, 200, 225, 300 mg; oral solution 20 mg/mL; Lyrica CR tablets 82.5, 165, 330 mg
Capsules 50, 100, 200, 400 mg; Elyxyb oral solution 25 mg/mL
Capsules: 3/25, 6/25, 6/50, 12/25, 12/50 mg olanzapine/fluoxetine
Carbonate 200, 400, 500, 600 mg elemental tablets and chewables; citrate 200, 250, 315 mg elemental; gluconate 1 g (94 mg elemental, 4.65 mEq) IV; chloride 1 g (270 mg elemental, 13.6 mEq) IV
Clozaril 25 mg and 100 mg tablets; FazaClo orally disintegrating tablets (12.5/25/100/150/200 mg); Versacloz oral suspension 50 mg/mL. All brands subject to identical REMS ANC monitoring requirements. Generic tablets widely available.
Codeine/acetaminophen 15/300 (#2 historical), 30/300 (#3), 60/300 (#4) mg tablets; 12/120 mg/5 mL elixir
Cream, ointment, lotion, foam, solution, shampoo, spray at 0.025-0.05%; emollient and non-emollient bases
Desoxyn 5 mg tabs
Dextromethorphan 45 mg + bupropion 105 mg ER tablets
Dried leaves and twigs, infused in a gourd (''mate'') and drunk through a metal straw (''bombilla'')
Dried leaves, infused. Six major processings: white, green, yellow, oolong, black, pu-erh
Dried leaves; absinthe liqueur (120–160 proof, with hyssop, lemon balm, fennel, anise, sometimes Acorus calamus)
ER tablets 25, 50, 100 mg
Extended-release tablets 1, 2, 3, 4 mg (Intuniv); immediate-release tablets 1, 2 mg (Tenex)
Fermented and roasted seeds, ground. Mexican tradition: drunk with chili, cornmeal, achiote. European tradition: with sugar and milk
Flowers or leaves infused or smoked. Highly variable potency; narrow toxic margin
Fresh leaves and tender twigs chewed; degrades on drying
Fresh nuts chewed; also dried and powdered
Gels, patches, IM cypionate/enanthate/undecanoate, buccal tabs, nasal gel, oral undecanoate, subcutaneous pellets
Ground dried seed (nutmeg) or fruit aril (mace); occasionally infused
Historical: Sernyl 25 mg tablets, 10 mg/mL injection (human); Sernylan 100 mg/mL injection (veterinary). Illicit: white crystalline powder, oily liquid, "dipped" cigarettes ("wet"), tablets.
IR 30, 60, 90, 120 mg tablets; multiple ER capsules and tablets 60-420 mg; IV 5 mg/mL
IR 40, 80, 120 mg tablets; SR/ER 100-360 mg; IV 2.5 mg/mL
IR tablets 0.1, 0.2, 0.3 mg; ER tablets 0.1, 0.2 mg (Kapvay); transdermal patches 0.1, 0.2, 0.3 mg/24h (TTS-1/2/3, weekly); epidural injection (Duraclon)
IR tablets 0.125, 0.25, 0.5, 0.75, 1, 1.5 mg; ER tablets 0.375, 0.75, 1.5, 2.25, 3, 3.75, 4.5 mg
IR tablets 0.25, 0.5, 1, 2, 3, 4, 5 mg; XL tablets 2, 4, 6, 8, 12 mg
IR tablets 10, 20, 30, 40 mg; CR tablets 12.5, 25, 37.5 mg; oral suspension 10 mg/5 mL; Brisdelle capsules 7.5 mg
IR tablets 15, 30 mg; oral solution 10 mg/5 mL, 20 mg/mL, 100 mg/5 mL (concentrated); suppositories; ER tablets and capsules in multiple strengths; injectable 0.5-50 mg/mL
IR tablets 150, 300, 600 mg; oral suspension 60 mg/mL; XR tablets 150, 300, 600 mg (Oxtellar)
IR tablets 200 mg; chewable 100 mg; oral suspension 100 mg/5 mL; XR tablets 100, 200, 400 mg (Tegretol XR); ER capsules 100, 200, 300 mg (Carbatrol, Equetro)
IR tablets 25, 100, 150, 200 mg; chewable dispersible tablets 2, 5, 25 mg; ODT 25, 50, 100, 200 mg; XR tablets 25, 50, 100, 200, 250, 300 mg
IR tablets 25, 37.5, 50, 75, 100 mg; XR capsules 37.5, 75, 150, 225 mg
IR tablets 25, 50 mg; ER tablets 100 mg; Cataflam IR 50 mg; Zorvolex 18, 35 mg; Voltaren gel 1%; Pennsaid 2% topical solution; Flector transdermal patch; Solaraze 3% gel; Cambia oral powder 50 mg
IR tablets 25, 50, 100 mg; Luvox CR capsules 100, 150 mg
IR tablets 25, 50, 100, 200 mg; sprinkle capsules 15, 25 mg; Trokendi XR capsules 25, 50, 100, 200 mg; Qudexy XR capsules; Eprontia oral solution 25 mg/mL
IR tablets 250, 500, 750, 1000 mg; XR tablets 500, 750 mg; oral solution 100 mg/mL; injection 100 mg/mL; Spritam ODT 250, 500, 750, 1000 mg
IR tablets 3.125, 6.25, 12.5, 25 mg; Coreg CR capsules 10, 20, 40, 80 mg (once-daily)
IR tablets 30, 60 mg; 12-hour ER tablets 120 mg; 24-hour ER tablets 240 mg; oral liquid; multiple combination products with antihistamines, NSAIDs, or expectorants
IR tablets 5, 10 mg; CR tablets 6.25, 12.5 mg; SL tablets 1.75, 3.5, 5, 10 mg; oral spray
IR tablets 5, 10 mg; oral solution 2 mg/mL; XR capsules 7, 14, 21, 28 mg
IR tablets 5, 7.5, 10 mg; Amrix ER capsules 15, 30 mg
IR tablets 5, 7.5, 10, 15, 20, 30 mg; IR oral solution 5 mg/5 mL; concentrated solution 20 mg/mL; OxyContin ER tablets 10, 15, 20, 30, 40, 60, 80 mg; Xtampza ER capsules
IR tablets 50 mg; ER tablets 100, 200, 300 mg (Ultram ER, ConZip); oral solution 5 mg/mL; combination products with acetaminophen (Ultracet)
IR tablets 50, 100, 150, 300 mg; Oleptro ER tablets 150, 300 mg
IR tabs 5, 7.5, 10, 12.5, 15, 20, 30 mg; XR caps 5, 10, 15, 20, 25, 30 mg; Mydayis caps 12.5, 25, 37.5, 50 mg
IV 10 mg/mL, 40 mg/mL; inhaled 300 mg/5 mL solution (Tobi, Bethkis); Podhaler dry powder; 0.3% ophthalmic solution and ointment
Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists.
Inhaled MDI 44/110/220 mcg per actuation; DPI (Diskus) 50/100/250 mcg; nasal spray 50 mcg/actuation; cream/ointment 0.005%, 0.05%
Injection 0.5-4% solutions (with and without epinephrine); topical cream 4-5%; transdermal patch 5% (Lidoderm), 1.8% (ZTLido); oral 2% viscous solution; jelly 2%; ophthalmic
Investigational oral capsule
Leaves and seeds, traditionally smoked or infused. Possibly the original Pythia oracle plant
Leaves chewed with a pinch of slaked lime (the lime converts cocaine HCl to freebase for buccal absorption); also drunk as tea (''mate de coca'')
Leaves, berries, root. Historically: belladonna cigarettes ("Asthmador") OTC in US until the 1970s
Lithium carbonate: immediate-release capsules (150 mg, 300 mg, 600 mg) and tablets (300 mg); extended-release tablets (300 mg, 450 mg). Lithium citrate: oral solution (8 mEq/5 mL, equivalent to 300 mg lithium carbonate per 5 mL) for patients unable to swallow tablets.
MDI 90 mcg/puff; nebulizer solution 0.083% (2.5 mg/3 mL), 0.5%, 0.021%, 0.042%; syrup 2 mg/5 mL; 2 mg, 4 mg tablets; 4 mg, 8 mg ER
Mononitrate 10, 20 mg IR; 30, 60, 120 mg ER; dinitrate 5, 10, 20, 30, 40 mg IR and ER
Multiple non-bioequivalent fenofibrate and fenofibric acid formulations: 48-200 mg
Multiple non-bioequivalent oral formulations (pH-, time-, and moisture-dependent release); rectal enema 4 g/60 mL; 1 g rectal suppository
Nasonex 50 mcg/actuation intranasal; Asmanex HFA MDI 100/200 mcg; Asmanex Twisthaler DPI 110/220 mcg; Elocon 0.1% cream/ointment/lotion; Sinuva sinus implant; Dulera (with formoterol)
OTC 400, 1,000, 2,000, 5,000 IU softgels and tablets; Rx 50,000 IU capsules; liquid drops 400-2,000 IU/drop
OTC IR niacin 50-500 mg tablets; Niaspan ER 500, 750, 1000 mg tablets; "no-flush" niacin (inositol hexaniacinate, lacks evidence)
OTC tablets 220 mg; Rx tablets 250, 375, 500 mg; ER tablets 375, 500, 750 mg (Naprelan); oral suspension 125 mg/5 mL; enteric-coated tablets (EC-Naprosyn)
OTC tablets, sublingual tablets, gummies, liquid, extended-release tablets and capsules; common strengths 0.5, 1, 3, 5, 10 mg
Oral 0.5, 1, 2 mg tablets; transdermal patches (twice-weekly and once-weekly); 0.06% gel; 1.53 mg/spray topical; vaginal ring (Estring); vaginal tablet (Vagifem/Yuvafem); vaginal cream
Oral 100, 200 mg capsules (peanut oil; check allergy); 100 mg vaginal insert (Endometrin); 4%, 8% vaginal gel (Crinone); IM 50 mg/mL
Oral tablets 25, 50, 100 mg; SC injection 4, 6 mg autoinjector; needle-free SC 6 mg (Sumavel); nasal spray 5, 20 mg; nasal powder 22 mg (Onzetra Xsail); low-dose autoinjector 3 mg (Zembrace SymTouch)
Oral tablets 5, 10, 23 mg; ODT 5, 10 mg; Adlarity transdermal patch 5, 10 mg/day (weekly application)
Oral tablets 50 mg (ReVia, Depade, generics); Vivitrol extended-release IM suspension 380 mg single-dose vial; Contrave (naltrexone 8 mg + bupropion 90 mg ER tablets); compounded 1, 2, 3, 4.5 mg tablets/capsules for LDN
Orally disintegrating tablet 75 mg
Oxide 400, 500 mg tablets (240, 300 mg elemental); citrate 100, 150, 200 mg tablets; hydroxide oral suspension 400 mg/5 mL; sulfate IV 500 mg/mL ampules
Oxycodone/acetaminophen 2.5/325, 5/325, 7.5/325, 10/325 mg tablets; 5/325 mg/5 mL solution
Parotid-gland venom expressed onto a glass plate, dried into a shellac-like resin, vaporized and inhaled
Powder for oral solution in 4 L jugs (PEG 3350 ~236 g + NaCl, NaHCO3, KCl, Na2SO4) and low-volume packets
Pre-filled multi-dose pen (0.25 / 0.5 / 1 / 2 mg, Ozempic;'"`UNIQ--ref-00000248-QINU`"' 0.25 / 0.5 / 1 / 1.7 / 2.4 mg, Wegovy'"`UNIQ--ref-00000249-QINU`"') · Oral tablet 3 / 7 / 14 mg co-formulated with SNAC absorption enhancer (Rybelsus)'"`UNIQ--ref-0000024A-QINU`"'
Pre-filled multi-dose pen (3 mL): Victoza 6 mg/mL (0.6 / 1.2 / 1.8 mg per day);'"`UNIQ--ref-00000183-QINU`"' Saxenda 6 mg/mL (0.6 / 1.2 / 1.8 / 2.4 / 3.0 mg per day)'"`UNIQ--ref-00000184-QINU`"'
Pre-filled single-dose pen and vial: 2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg'"`UNIQ--ref-000002FC-QINU`"''"`UNIQ--ref-000002FD-QINU`"'
Pre-filled single-dose pen: 0.75 / 1.5 / 3 / 4.5 mg'"`UNIQ--ref-00000054-QINU`"'
Pulmicort Flexhaler DPI 90, 180 mcg/dose; Pulmicort Respules 0.25, 0.5, 1 mg/2 mL nebulized; Rhinocort intranasal 32 mcg/spray; Entocort EC 3 mg capsules; Uceris 9 mg ER tablets and rectal foam
Roasted beans, ground; brewed (drip, French press, espresso, cold brew, percolated)
Roasted seeds ground to powder, mixed with water; commercial syrups and energy drinks
Root bark acid/base-extracted for DMT; or as the resurrected ''jurema preta'' brew (decocted with an MAOI such as ''Peganum harmala'')
Root, traditionally carved into ''mannikens'' or infused into wine
SL 0.3, 0.4, 0.6 mg tablets; lingual spray 0.4 mg/spray; ER 2.5-9 mg capsules; transdermal patch 0.1-0.8 mg/hr; 2% ointment; 0.4% rectal ointment; 5 mg/mL IV
SL film or tablet, 2/0.5 to 12/3 mg per dose
SR tablets 100, 150, 200 mg; XL tablets 150, 300 mg; IR tablets 75, 100 mg (less common); Aplenzin (bupropion hydrobromide) 174, 348, 522 mg
Sandimmune 25, 100 mg capsules; Neoral 25, 100 mg modified soft gel; 100 mg/mL oral solution; 50 mg/mL IV; Restasis 0.05% ophthalmic emulsion
Synthesized psilocybin capsules (COMP360 and other investigational formulations); dried whole [[Psilocybe|Psilocybe]] mushrooms (variable potency, no legal supply chain in most jurisdictions); psilocybin truffles (Psilocybe sclerotia, legal in the Netherlands)
Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen).
Tablets 0.25, 0.5, 1, 2, 3, 4 mg; M-Tab ODT 0.5, 1, 2, 3, 4 mg; oral solution 1 mg/mL; Consta LAI 12.5, 25, 37.5, 50 mg; Perseris SC LAI 90, 120 mg monthly
Tablets 0.5, 1, 2 mg; oral concentrate 2 mg/mL; injection 2 mg/mL and 4 mg/mL; Loreev XR capsules 1, 2, 3 mg
Tablets 0.5, 1, 2 mg; orally disintegrating tablets 0.125, 0.25, 0.5, 1, 2 mg
Tablets 10 mg; injection 15 mg/mL and 30 mg/mL; nasal spray 15.75 mg/spray (Sprix); ophthalmic solution 0.4%, 0.45%, 0.5%
Tablets 10, 20, 40 mg; oral solution 10 mg/5 mL
Tablets 10, 25, 50 mg (HCl); capsules 25, 50, 100 mg (pamoate); oral suspension 25 mg/5 mL; injection 25, 50 mg/mL (IM only, never IV)
Tablets 10, 25, 50, 75, 100, 150 mg
Tablets 100, 200, 300 mg; injection 5 mg/mL
Tablets 12.5, 25 mg; chewable tablets 25 mg
Tablets 12.5, 25, 50 mg; oral syrup 6.25 mg/5 mL; suppositories 12.5, 25, 50 mg; injection 25 mg/mL and 50 mg/mL
Tablets 2, 4 mg; capsules 2, 4, 6 mg ('''capsules and tablets are not bioequivalent''': capsules slower with food; tablets faster on empty stomach)
Tablets 2, 5, 10 mg; oral solution 1, 5 mg/mL; injection 5 mg/mL; Diastat rectal gel 2.5, 5, 10, 20 mg; Valtoco nasal spray 5, 7.5, 10 mg/dose; Libervant buccal film
Tablets 2, 5, 10, 15, 20, 30 mg; ODT 10, 15 mg; oral solution 1 mg/mL; acute IM injection 9.75 mg/1.3 mL; Maintena LAI 300, 400 mg monthly; Aristada LAI 441, 662, 882, 1064 mg (4-8 week dosing); Asimtufii bi-monthly
Tablets 2.5, 5, 7.5, 10, 15, 20 mg; ODT (Zydis) 5, 10, 15, 20 mg; acute IM injection 10 mg/vial; Relprevv LAI 210, 300, 405 mg vials
Tablets 200, 400, 600, 800 mg; capsules 200 mg; oral suspension 100 mg/5 mL; chewable tablets 100 mg; injection 100 mg/mL (Caldolor)
Tablets 25, 50 mg; capsules; liquid; chewable; topical cream/gel; injection 50 mg/mL
Tablets 25, 50, 100 mg
Tablets 4 mg; oral syrup 2 mg/5 mL
Tablets 5, 10 mg; ODT (Maxalt-MLT) 5, 10 mg
Tablets 5, 10, 20 mg; ophthalmic solution 0.25%, 0.5%; ophthalmic gel-forming solution 0.25%, 0.5% (Timoptic-XE)
Tablets 5, 10, 20 mg; oral solution 1 mg/mL
Tablets 5, 10, 20 mg; oral suspension 5 mg/5 mL (Ozobax, Fleqsuvy); intrathecal injection 50, 500, 1000, 2000 mcg/mL (Lioresal Intrathecal, Gablofen); oral granules (Lyvispah)
Tablets 5, 10, 40 mg (40 mg dispersible restricted to OTPs); oral concentrate 10 mg/mL; oral solution 1, 2, 10 mg/mL; injection 10 mg/mL
Tablets 5, 7.5, 10, 15, 30 mg (the 15 and 30 mg tablets are scored for halving and quartering)
Tablets 50, 250 mg
Tablets 500, 750 mg; injection 100 mg/mL
Tablets 7.5, 15 mg (Mobic); capsules 5, 10 mg (Vivlodex); oral suspension 7.5 mg/5 mL; injection 30 mg/mL (Anjeso)
Tablets 7.5, 15, 30, 45 mg; orally disintegrating tablets (SolTab) 15, 30, 45 mg
Tablets 81 (low-dose), 325, 500, 650 mg; chewable 81 mg; enteric-coated tablets; effervescent tablets; suppositories
Tablets: 100 mg, 200 mg (scored). [[Armodafinil]] (Nuvigil), the R-enantiomer of modafinil, is available separately as 50 mg, 150 mg, 200 mg, and 250 mg tablets.
Tartrate: 25, 50, 100 mg tabs; 1 mg/mL IV. Succinate ER: 25, 50, 100, 200 mg.
Toasted leaves and twigs decocted to a near-black concentrate
Toothpaste, rinse, gel, varnish (topical); 0.25, 0.5, 1 mg tablets and drops (Rx supplements where appropriate)
Topical 0.01-0.1% creams, gels, micropsheres, lotions; oral 10 mg capsules (Vesanoid)
Topical creams, ointments, lotions, dental paste (0.025-0.5%); Kenalog 10 mg/mL, 40 mg/mL injection; Nasacort 55 mcg/spray intranasal; oral inhaler discontinued in US
Tramadol/acetaminophen 37.5/325 mg tablets
Was: 170 mg/1.7 mL, 300 mg/3 mL vials for IV infusion
Search
fda max:
100 mg/day (vertigo) (1)
routes:
Oral (1)
onset:
~1 hour (1)
duration:
12-24 hours (long for an antihistamine) (1)
halflife:
(Click arrow to add another value)
None
·
~12 hours
·
~27 days
·
~5 h (caffeine)
·
'''Autoinduction''': 25-65 hours initially, falling to 12-17 hours after 2-3 weeks of dosing as carbamazepine induces its own CYP3A4 metabolism. Major clinical implication: doses require re-titration after the autoinduction period'"`UNIQ--ref-0000001D-QINU`"'
·
0.5-1.5 hours (plasma); pharmacodynamic effect persists 24+ hours'"`UNIQ--ref-000000DE-QINU`"'
·
1-1.3 hours'"`UNIQ--ref-000001A1-QINU`"'
·
1-1.5 hours'"`UNIQ--ref-00000DE3-QINU`"'
·
1-2 hours (parent compound)'"`UNIQ--ref-00000029-QINU`"'
·
1-2 hours (parent); 18-30 hours for active metabolite oxypurinol'"`UNIQ--ref-0000030F-QINU`"'
·
1-2 hours'"`UNIQ--ref-00000017-QINU`"'
·
1-3 hours (normal liver); markedly prolonged in overdose with glutathione depletion'"`UNIQ--ref-000006A5-QINU`"'
·
1-3 minutes (very short)'"`UNIQ--ref-00000C0F-QINU`"'
·
1.4 hours (parent); 13-24 hours for active metabolite canrenone'"`UNIQ--ref-00000354-QINU`"'
·
1.5-2 hours (longer in renal failure)'"`UNIQ--ref-00000222-QINU`"'
·
1.5-2 hours'"`UNIQ--ref-00000020-QINU`"'
·
10-11 hours (benazeprilat, the active metabolite)'"`UNIQ--ref-00000A22-QINU`"'
·
11-13 h (immediate-release); 11-16 h (extended-release)
·
11-15 hours'"`UNIQ--ref-00000842-QINU`"'
·
12-15 hours (intermediate); '''no active metabolites''' (key clinical feature)'"`UNIQ--ref-00000023-QINU`"'
Other values:
12-15 hours'"`UNIQ--ref-00000022-QINU`"'
12-16 hours'"`UNIQ--ref-00000026-QINU`"'
12-17 hours'"`UNIQ--ref-00000029-QINU`"'
14 hours (parent); 20-30 hours including active ortho- and para-hydroxylated metabolites'"`UNIQ--ref-0000001B-QINU`"'
14-25 hours (longer in elderly and hepatic impairment)'"`UNIQ--ref-00000026-QINU`"'
14–26 h (oral); ~3 weeks (decanoate)
15-20 hours'"`UNIQ--ref-00000020-QINU`"'
16-22 hours'"`UNIQ--ref-0000047D-QINU`"'
18 hours (IR); 32-33 hours (ER)'"`UNIQ--ref-0000001A-QINU`"'
18-44 hours'"`UNIQ--ref-00000020-QINU`"'
1–4 days (7–15 days for norfluoxetine)
2 hours (parent); 6-9 hours for active carboxylic acid metabolite EXP3174'"`UNIQ--ref-000000BC-QINU`"'
2 hours'"`UNIQ--ref-00000015-QINU`"'
2-3 hours (normal renal function); markedly prolonged in renal impairment'"`UNIQ--ref-000010B3-QINU`"'
2-3 hours (parent and active N-desethyl metabolite)'"`UNIQ--ref-000006E1-QINU`"'
2-3 hours'"`UNIQ--ref-00000012-QINU`"'
2-4 hours'"`UNIQ--ref-00000026-QINU`"'
2-5 hours (IR); ER formulations extend functional duration via osmotic/matrix release'"`UNIQ--ref-0000074D-QINU`"'
2-5 hours'"`UNIQ--ref-000002D9-QINU`"'
2.2 h (IR parent); ~3 h (XR parent)
2.5 hours (short, requires TID-QID dosing)'"`UNIQ--ref-0000001D-QINU`"'
2.5-3.5 hours; longer in renal impairment'"`UNIQ--ref-0000025B-QINU`"'
2.5–3 hours
2.7-5.5 hours'"`UNIQ--ref-0000015E-QINU`"'
20-40 hours'"`UNIQ--ref-00000023-QINU`"'
21-54 hours'"`UNIQ--ref-00000026-QINU`"'
24–42 h (buprenorphine); 1–2 h (naloxone)
27-32 hours'"`UNIQ--ref-00000026-QINU`"'
2–3 h
2–3 h (parent compound)
3-10 hours (low dose); 8-15 hours (high dose); much longer in third-space accumulation (pleural effusion, ascites)'"`UNIQ--ref-000007C8-QINU`"'
3-4 hours (similar between PO and IV due to high oral bioavailability)'"`UNIQ--ref-00000B46-QINU`"'
3-4 hours'"`UNIQ--ref-00000026-QINU`"'
3-4.5 hours (IR); 5-7 hours (ER; effective duration 24 hours via formulation)'"`UNIQ--ref-00000642-QINU`"'
3-5 hours (IR); 4.5 hours (ER)'"`UNIQ--ref-0000001D-QINU`"'
3-6 hours (longer in hepatic impairment)'"`UNIQ--ref-00000378-QINU`"'
3-7 hours (IR); functional 24 hours (ER)'"`UNIQ--ref-00000A6B-QINU`"'
3-7 hours (slow acetylators) vs 1-3 hours (rapid acetylators) via NAT2 polymorphism'"`UNIQ--ref-00000687-QINU`"'
30-40 hours (long; accumulates with chronic dosing)'"`UNIQ--ref-00000026-QINU`"'
30-50 hours'"`UNIQ--ref-00000078-QINU`"'
30-50 minutes (short)'"`UNIQ--ref-00000021-QINU`"'
30–60 min
36-42 hours (R/S enantiomers differ; S-warfarin is 2-5× more potent and cleared by CYP2C9)'"`UNIQ--ref-00000705-QINU`"'
3–5 hours
3–6 h
3–7 h
4 hours'"`UNIQ--ref-00000938-QINU`"'
4-5 hours'"`UNIQ--ref-00000026-QINU`"'
4-6 hours (inhaled and PO)'"`UNIQ--ref-00000099-QINU`"'
4-8 hours (longer in elderly, 9-13 hours)'"`UNIQ--ref-00000026-QINU`"'
40-60 hours (notable for the thiazide class)'"`UNIQ--ref-00000783-QINU`"'
4–5 h
5-6 hours'"`UNIQ--ref-00000020-QINU`"'
5-6 hours'"`UNIQ--ref-00000EF9-QINU`"'
5-7 hours'"`UNIQ--ref-00000029-QINU`"'
5-9 hours (elderly: 11-13 hours)'"`UNIQ--ref-00000513-QINU`"'
6-15 hours'"`UNIQ--ref-0000013E-QINU`"'
6-8 hours'"`UNIQ--ref-0000001F-QINU`"'
6-8 hours'"`UNIQ--ref-00000BEB-QINU`"'
6-9 hours (substantially longer in renal impairment due to renal elimination)'"`UNIQ--ref-00000020-QINU`"'
6.2 hours (plasma); ~17 hours in erythrocytes'"`UNIQ--ref-00000018-QINU`"'
6.3 hours'"`UNIQ--ref-00000026-QINU`"'
60-100 hours (long)'"`UNIQ--ref-0000001B-QINU`"'
7-10 hours'"`UNIQ--ref-0000001B-QINU`"'
8-10 hours (longer in elderly and renal impairment)'"`UNIQ--ref-00000396-QINU`"'
8-12 hours (longer in elderly and renal impairment)'"`UNIQ--ref-0000001B-QINU`"'
8-16 hours'"`UNIQ--ref-0000001E-QINU`"'
9-15 hours'"`UNIQ--ref-000001BC-QINU`"'
9-16 hours (pH-dependent: acidic urine shortens, alkaline urine substantially extends)'"`UNIQ--ref-0000001B-QINU`"'
9-16 hours'"`UNIQ--ref-0000097C-QINU`"'
9–12 h
9–12 minutes (intravenous)
Amitriptyline 10-50 hours (highly variable); nortriptyline active metabolite 18-44 hours'"`UNIQ--ref-00000026-QINU`"'
Approximately 18-24 hours after acute administration; may extend to 36-48 hours with chronic dosing as tissue compartments equilibrate. Serum trough levels should be drawn 12 hours after the last dose for accurate interpretation.'"`UNIQ--ref-00000055-QINU`"'
Aqueous crystalline ~30 minutes; benzathine effective ~3 weeks via depot release'"`UNIQ--ref-00001419-QINU`"'
Aspirin 15-30 minutes; salicylate metabolite 2-3 hours (concentration-dependent, saturable at high doses)'"`UNIQ--ref-00000027-QINU`"'
Biphasic: ~3-6 hours alpha, ~5-9 hours beta'"`UNIQ--ref-0000001D-QINU`"'
Buprenorphine sublingual: 24-42 hours (long, contributes to extended dosing intervals). Norbuprenorphine (active metabolite, weaker mu-agonist): 24-48 hours.'"`UNIQ--ref-0000004F-QINU`"'
Bupropion ~21 hours; hydroxybupropion (active metabolite) ~20-37 hours'"`UNIQ--ref-00000023-QINU`"'
Buspirone 2-3 hours; 1-PP active metabolite 4-6 hours'"`UNIQ--ref-0000001D-QINU`"'
Butalbital ~35 hours (long; cumulative effects with frequent use); acetaminophen 1-3 hours; caffeine 3-7 hours'"`UNIQ--ref-0000159F-QINU`"'
Butalbital ~35 hours; aspirin (acetyl group) ~15 minutes, salicylate 2-3 hours; caffeine 3-7 hours'"`UNIQ--ref-000015B7-QINU`"'
Cariprazine ~2-4 d; major active metabolites desmethyl-cariprazine (DCAR) ~1-3 weeks → 'oral depot' effect with delayed steady-state and reduced effect of missed doses
Codeine 2.5-3.5 hours; acetaminophen 1-3 hours'"`UNIQ--ref-00001517-QINU`"'
D-amphetamine ~10 h; L-amphetamine ~13 h (adults)
Dextromethorphan substantially prolonged by quinidine's CYP2D6 inhibition (typical extensive metabolizers see ~10× higher AUC); quinidine ~6-8 hours'"`UNIQ--ref-00001583-QINU`"'
Dextromethorphan ~22 h (when CYP2D6 inhibited); bupropion ~21 h
Diazepam 20-50 hours; '''N-desmethyldiazepam (nordazepam) 30-200 hours''' is the major active metabolite and accumulates substantially with chronic dosing'"`UNIQ--ref-00000026-QINU`"'
Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect.
Highly variable by formulation; native T is hours
Highly variable, 7-46 hours (mean ~21 h); lipophilic deposition in fat with delayed re-release contributes to wide range'"`UNIQ--ref-00000065-QINU`"'
Mononitrate ~5 hours; dinitrate ~1 hour'"`UNIQ--ref-00001461-QINU`"'
Morphine 2-4 hours; morphine-6-glucuronide active metabolite 2-4 hours (longer with renal impairment)'"`UNIQ--ref-00000020-QINU`"'
N/A (incorporated into hemoglobin and tissue stores)
Naltrexone parent ~4 hours (oral); 6-beta-naltrexol (active metabolite) ~13 hours. Vivitrol depot terminal half-life 5-10 days with sustained release from microspheres maintaining blockade for the 4-week dosing interval.'"`UNIQ--ref-0000004F-QINU`"'
Naltrexone ~4 hours (6β-naltrexol metabolite ~13 hours); bupropion ~21 hours'"`UNIQ--ref-00001568-QINU`"'
Not absorbed
Not applicable (electrolyte and buffer)
Not applicable (electrolyte solution)
Not applicable (electrolyte)
Not formally established
Not meaningfully described
Not meaningfully described (electrolyte)
Not meaningfully described (electrolyte; renally cleared)
Not meaningfully described (minimal systemic absorption from topical use)'"`UNIQ--ref-00000F45-QINU`"'
Not meaningfully described (negligible systemic absorption from intact skin or oral mucosa)'"`UNIQ--ref-00001398-QINU`"'
Not meaningfully described (negligible systemic absorption — the drug acts locally and is degraded in the GI tract)'"`UNIQ--ref-0000119C-QINU`"'
Not meaningfully described (negligible systemic absorption)
Not meaningfully described (not systemically absorbed)'"`UNIQ--ref-00000D17-QINU`"'
Not meaningfully described (topical local action)'"`UNIQ--ref-00001239-QINU`"'
Not meaningfully described for an electrolyte; distribution between intra- and extracellular compartments is the relevant kinetic
Not meaningfully described for ophthalmic use'"`UNIQ--ref-00001287-QINU`"'
Not meaningfully described for topical use (systemic exposure varies with surface area, occlusion, skin integrity)'"`UNIQ--ref-0000079E-QINU`"'
Not meaningfully described for topical use'"`UNIQ--ref-00000A02-QINU`"'
Not meaningfully described — lactulose is not significantly absorbed
Not meaningfully described — sucralfate is essentially non-absorbed'"`UNIQ--ref-00000DC2-QINU`"'
Not meaningfully described — topical local action with minimal systemic absorption'"`UNIQ--ref-00001218-QINU`"'
Not well characterized
Not well characterized; tissue incorporation over weeks'"`UNIQ--ref-00000051-QINU`"'
Not well characterized'"`UNIQ--ref-00000018-QINU`"'
Olanzapine ~30 hours; fluoxetine 1-4 days (norfluoxetine 7-15 days)'"`UNIQ--ref-0000154D-QINU`"'
Oxcarbazepine 2 hours; '''10-monohydroxy active metabolite (MHD) ~9 hours''' (the agent that produces essentially all of the clinical effect)'"`UNIQ--ref-0000001A-QINU`"'
Oxycodone 3-5 hours; acetaminophen 1-3 hours'"`UNIQ--ref-000014E2-QINU`"'
Oxycodone 3-5 hours; aspirin (acetyl group) 15-20 minutes, salicylate 2-3 hours at therapeutic doses'"`UNIQ--ref-000014FA-QINU`"'
Parent lisdexamfetamine <1 hour; dextroamphetamine 10-12 hours after release'"`UNIQ--ref-00000017-QINU`"'
Plasma 2-3 hours; biologic ~18-36 hours'"`UNIQ--ref-00000867-QINU`"'
Plasma 2-3 hours; biologic ~18-36 hours'"`UNIQ--ref-000008C4-QINU`"'
Plasma 3-4 hours; biologic ~12-36 hours'"`UNIQ--ref-000002A3-QINU`"'
Plasma ~1-2 hours; biologic ~8-12 hours'"`UNIQ--ref-00000AD1-QINU`"'
Plasma ~3 hours; bone half-life ~10 years'"`UNIQ--ref-000006C3-QINU`"'
Plasma ~3-4.5 hours; biologic ~36-72 hours'"`UNIQ--ref-00000E2B-QINU`"'
Plasma ~3-5 hours; biologic effect substantially longer (~12-36 hours for intermediate-acting glucocorticoids)'"`UNIQ--ref-00000666-QINU`"'
Plasma ~5 hours; biologic ~36-54 hours'"`UNIQ--ref-0000101A-QINU`"'
Primidone 5-15 hours; '''phenobarbital active metabolite 50-150 hours'''; PEMA (phenylethylmalonamide) active metabolite 16 hours'"`UNIQ--ref-00000017-QINU`"'
Psilocin: ~2-3 h; psilocybin itself is a prodrug, dephosphorylated within minutes of absorption
Risperidone 3-20 hours; '''9-hydroxy-risperidone (paliperidone) ~20-24 hours''' is the major active metabolite and is separately marketed as a parent compound (Invega)'"`UNIQ--ref-00000021-QINU`"'
Sumatriptan ~2.5 hours; naproxen 12-15 hours'"`UNIQ--ref-000015D1-QINU`"'
T4 ~7 days; T3 ~1 day'"`UNIQ--ref-00000036-QINU`"'
Tissue half-life not formally measured; clinical effect ~12 weeks
Topical: not meaningfully described; oral 2-8 hours'"`UNIQ--ref-00000888-QINU`"'
Tramadol 6-7 hours; M1 active metabolite 7-9 hours'"`UNIQ--ref-0000001D-QINU`"'
Tramadol ~5-7 hours (M1 metabolite ~9 hours); acetaminophen 1-3 hours'"`UNIQ--ref-00001530-QINU`"'
Variable; effect dependent on local intestinal action rather than systemic kinetics'"`UNIQ--ref-0000106B-QINU`"'
Venlafaxine 5 hours; desvenlafaxine active metabolite 11 hours'"`UNIQ--ref-00000026-QINU`"'
~0.5 hours plasma; tissue retention longer
~0.5-2 hours (oral)'"`UNIQ--ref-00000BA3-QINU`"'
~1 day (much shorter than T4's ~7 days)'"`UNIQ--ref-0000149D-QINU`"'
~1 hour (IR niacin); ER formulations extend functional duration'"`UNIQ--ref-00001038-QINU`"'
~1 hour (plasma); pharmacodynamic effect persists 24+ hours'"`UNIQ--ref-0000011D-QINU`"'
~1 hour SC'"`UNIQ--ref-00000589-QINU`"'
~1 hour'"`UNIQ--ref-000004F2-QINU`"'
~1 hour'"`UNIQ--ref-00001050-QINU`"'
~1-2 hours plasma (riboflavin itself); FAD/FMN tissue cofactors are continuous
~1.5 hours (plasma); pharmacodynamic effect 24+ hours via target turnover'"`UNIQ--ref-000008E8-QINU`"'
~1.5 hours'"`UNIQ--ref-00000FF9-QINU`"'
~1.5-2 hours'"`UNIQ--ref-00000D3E-QINU`"'
~1.7 hours'"`UNIQ--ref-000009E4-QINU`"'
~1.8 hours (initial); ~10 hours (terminal)'"`UNIQ--ref-00000B25-QINU`"'
~10 h (CYP2D6 extensive metabolizers); up to 31 h (poor metabolizers)
~10-20 days (steady-state body pool); single dose plasma ~2 hours
~10-20 minutes systemically (rapid hepatic and erythrocyte dihydropyrimidine dehydrogenase clearance)'"`UNIQ--ref-000011BE-QINU`"'
~11 h
~11 hours (enalaprilat, the active metabolite)'"`UNIQ--ref-00000B84-QINU`"'
~11 hours'"`UNIQ--ref-00000015-QINU`"'
~11 hours'"`UNIQ--ref-0000001A-QINU`"'
~11 hours'"`UNIQ--ref-00000029-QINU`"'
~11-17 days'"`UNIQ--ref-0000147F-QINU`"'
~12 hours (effective); terminal half-life is biphasic'"`UNIQ--ref-00000059-QINU`"'
~12 hours (effective); terminal much longer'"`UNIQ--ref-0000117C-QINU`"'
~12 hours apparent (functional duration ~24 hours due to depot release kinetics)'"`UNIQ--ref-0000023B-QINU`"'
~12 hours'"`UNIQ--ref-000001FB-QINU`"'
~12 hours'"`UNIQ--ref-00000D82-QINU`"'
~12 hours'"`UNIQ--ref-0000111F-QINU`"'
~12.1 days
~12.4 hours'"`UNIQ--ref-0000027C-QINU`"'
~12.4 hours'"`UNIQ--ref-00000765-QINU`"'
~12.9 hours'"`UNIQ--ref-00000552-QINU`"'
~13 hours'"`UNIQ--ref-0000018A-QINU`"'
~13 hours'"`UNIQ--ref-0000056C-QINU`"'
~13-17 hours (ramiprilat, the active metabolite)'"`UNIQ--ref-00000C32-QINU`"'
~13-20 hours (oral); transdermal pharmacokinetics buffer the peaks/troughs of oral dosing'"`UNIQ--ref-000003BA-QINU`"'
~14 days'"`UNIQ--ref-00001103-QINU`"'
~14 hours (adults); longer in elderly and renal impairment'"`UNIQ--ref-0000113F-QINU`"'
~14 hours'"`UNIQ--ref-00000CCC-QINU`"'
~15 hours (IR)'"`UNIQ--ref-00000023-QINU`"'
~15 hours (parent); nordoxepin active metabolite ~30 hours'"`UNIQ--ref-00000020-QINU`"'
~16-18 hours'"`UNIQ--ref-00001092-QINU`"'
~16-23 hours
~165 hours (~1 week), among the longest of any GLP-1 RA'"`UNIQ--ref-00000253-QINU`"'
~17 minutes (free acid, the active form, in aqueous humor)'"`UNIQ--ref-00000417-QINU`"'
~17-18 hours (Intuniv ER); ~17 hours (immediate-release)'"`UNIQ--ref-00000020-QINU`"'
~17-19 hours (longer than daridorexant)
~17.5 h
~18 hours (terminal)
~19 hours'"`UNIQ--ref-000000FC-QINU`"'
~2 hours (parent and active β-hydroxy acid metabolite); pharmacodynamic effect lasts 24 hours via target turnover'"`UNIQ--ref-0000017A-QINU`"'
~2 hours (plasma; minimal relevance — local-action drug)'"`UNIQ--ref-00000F7B-QINU`"'
~2 minutes'"`UNIQ--ref-00000E52-QINU`"'
~2-3 hours (parent); pharmacodynamic effect 24 hours via target turnover'"`UNIQ--ref-000003D5-QINU`"'
~2-3.6 hours (plasma)'"`UNIQ--ref-000009A5-QINU`"'
~2-4 hours (parent and active β-hydroxy acid metabolite); pharmacodynamic effect 24 hours via target turnover'"`UNIQ--ref-00000807-QINU`"'
~2.4 hours (Byetta, short, hence the BID schedule)'"`UNIQ--ref-000000ED-QINU`"' · Effective release half-life ~2 weeks (Bydureon)'"`UNIQ--ref-000000EE-QINU`"'
~2.5 hours'"`UNIQ--ref-0000001A-QINU`"'
~2.5-3 hours'"`UNIQ--ref-00001442-QINU`"'
~20 hours
~20 hours (fenofibric acid, the active metabolite)'"`UNIQ--ref-000004AD-QINU`"'
~20-60 minutes (plasma; not the relevant kinetic since urinary concentration matters)'"`UNIQ--ref-000008A3-QINU`"'
~21 hours (with nonlinear pharmacokinetics from CYP2D6 autoinhibition)'"`UNIQ--ref-0000002B-QINU`"'
~21 hours'"`UNIQ--ref-00000028-QINU`"'
~22 hours (parent + active glucuronide)'"`UNIQ--ref-00000450-QINU`"'
~22 hours; longer 54 hours (desmethylazelastine, active metabolite)'"`UNIQ--ref-000013B6-QINU`"'
~22 hours'"`UNIQ--ref-00000AB0-QINU`"'
~24 hours (6-methoxy-2-naphthylacetic acid, the active metabolite)'"`UNIQ--ref-000011F9-QINU`"'
~24 hours (longest of the ARB class; suits patients with morning BP surge)'"`UNIQ--ref-00000AEE-QINU`"'
~24 hours (parent); ~15 days (25(OH)D); 25(OH)D stores persist for months'"`UNIQ--ref-00000330-QINU`"'
~24 hours (parent); ~15 days (25(OH)D); tissue stores months
~25 days
~25 hours
~25 hours apparent (functional duration well over 42 hours from multi-hexamer depot)'"`UNIQ--ref-0000135A-QINU`"'
~25 hours'"`UNIQ--ref-0000129F-QINU`"'
~25-33 hours alone; ~15 hours with enzyme inducers; '''≥60 hours with valproate''' (UGT inhibition)'"`UNIQ--ref-00000025-QINU`"'
~25-44 hours plasma; receptor kinetics drive the once-daily duration'"`UNIQ--ref-000009C0-QINU`"'
~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active)
~27-31 hours; markedly prolonged in renal/hepatic impairment and with CYP3A4 or P-gp inhibitors'"`UNIQ--ref-00000C72-QINU`"'
~28 days
~3 hours (acyclovir, the active metabolite); longer in renal impairment'"`UNIQ--ref-000005D6-QINU`"'
~3 hours (systemic, when measurable; topical action dominates)'"`UNIQ--ref-000011D9-QINU`"'
~3 hours; significantly prolonged in renal impairment'"`UNIQ--ref-0000090F-QINU`"'
~3 hours'"`UNIQ--ref-000010D1-QINU`"'
~3-4 days plasma; adipose tissue stores last months
~3-7 hours (parent); 16-24 hours including active metabolites'"`UNIQ--ref-00000824-QINU`"'
~30 hours (long, supports once-daily dosing and substantial drug-interaction window after discontinuation)'"`UNIQ--ref-00000A47-QINU`"'
~30-60 minutes'"`UNIQ--ref-00000E76-QINU`"'
~31 days
~35 hours'"`UNIQ--ref-00000026-QINU`"'
~36 hours (terminal much longer due to tissue accumulation in skin/nails)'"`UNIQ--ref-00000EB2-QINU`"'
~4 h
~4 hours (oral)'"`UNIQ--ref-0000001B-QINU`"'
~4 months in erythrocytes (carbonic anhydrase binding in red cells; not relevant to topical IOP duration)'"`UNIQ--ref-00000B0A-QINU`"'
~4-6 hours (plasma); intrathyroidal accumulation gives a much longer functional duration'"`UNIQ--ref-00000ED3-QINU`"'
~40 days (terminal; reflects extensive tissue distribution)'"`UNIQ--ref-000007EC-QINU`"'
~45 minutes (free acid in aqueous humor)'"`UNIQ--ref-00000DA1-QINU`"'
~45-68 hours'"`UNIQ--ref-00000DFE-QINU`"'
~5 days (~120 h)'"`UNIQ--ref-00000059-QINU`"'
~5 days (~120 h)'"`UNIQ--ref-00000303-QINU`"'
~5 h
~5 hours (plasma)'"`UNIQ--ref-00000F9C-QINU`"'
~5 hours in extensive CYP2D6 metabolizers; ~21 hours in CYP2D6 poor metabolizers'"`UNIQ--ref-00000014-QINU`"'
~5 weeks (much longer than finasteride's ~6 hours)'"`UNIQ--ref-00000D59-QINU`"'
~5-10 hours (5-ASA)'"`UNIQ--ref-00000BBE-QINU`"'
~5-20 hours (oral micronized; highly variable)'"`UNIQ--ref-00000726-QINU`"'
~5-6 hours in young men, ~8 hours in elderly'"`UNIQ--ref-00000531-QINU`"'
~5-7 days
~5-8 hours'"`UNIQ--ref-00001164-QINU`"'
~5-9 hours (parent and active metabolites combined)'"`UNIQ--ref-00000492-QINU`"'
~50 days (Depo-Provera; long depot release)'"`UNIQ--ref-00000F20-QINU`"'
~50 hours'"`UNIQ--ref-00000B64-QINU`"'
~50 hours'"`UNIQ--ref-00000C4E-QINU`"'
~57 hours (parent), ~200 h (active metabolite)
~58 days (parent); ~61 days (desethylamiodarone, active metabolite)'"`UNIQ--ref-00000CB3-QINU`"'
~6 days (plasma); hepatic stores last 3-5 years
~6 h (parent compound, immediate-release); ~9-12 h (active metabolite N-desalkylquetiapine, also called norquetiapine)
~6 hours (parent); active metabolite very short-lived but produces irreversible platelet effect'"`UNIQ--ref-000002C4-QINU`"'
~6 hours plasma; long bone retention
~6 hours'"`UNIQ--ref-00000015-QINU`"'
~6 hours'"`UNIQ--ref-00000018-QINU`"'
~6 hours'"`UNIQ--ref-000004CD-QINU`"'
~6-10 hours (oseltamivir carboxylate, the active metabolite)'"`UNIQ--ref-00000E94-QINU`"'
~6-8 hours'"`UNIQ--ref-0000001A-QINU`"'
~6-8 hours'"`UNIQ--ref-00000CF5-QINU`"'
~6.6 h
~60–80 h (memantine); ~70 h (donepezil)
~66 hours
~68 hours (terminal; reflects deep tissue accumulation, much longer than plasma)'"`UNIQ--ref-000003FC-QINU`"'
~7 days (euthyroid); longer in hypothyroidism (~9-10 days), shorter in hyperthyroidism'"`UNIQ--ref-00000036-QINU`"'
~7 hours
~7 hours (parent); ~9 hours (active AR-C124910XX metabolite, accounts for ~30-40% of activity)'"`UNIQ--ref-00000C92-QINU`"'
~7 hours apparent'"`UNIQ--ref-00001374-QINU`"'
~7 hours'"`UNIQ--ref-0000126E-QINU`"'
~7-10 hours (variable; longer in renal impairment)'"`UNIQ--ref-00000FB4-QINU`"'
~7-12 hours
~7.1 hours
~7.8 hours (fluticasone propionate, inhaled systemic exposure)'"`UNIQ--ref-000001DD-QINU`"'
~70 hours (long, supports once-daily dosing without peak-trough variation)'"`UNIQ--ref-0000001B-QINU`"'
~75 hours (long, accumulates over weeks)'"`UNIQ--ref-00000023-QINU`"'
~8 hours (longer in elderly and renal impairment)'"`UNIQ--ref-00000954-QINU`"'
~8 hours (parent); ~28 hours (desloratadine, the active metabolite, marketed separately as Clarinex)'"`UNIQ--ref-00000621-QINU`"'
~8 hours (shorter than suvorexant and lemborexant)
~8 hours'"`UNIQ--ref-000013F5-QINU`"'
~8-27 hours (highly variable across the population)'"`UNIQ--ref-00000A91-QINU`"'
~80 minutes SC'"`UNIQ--ref-000005F2-QINU`"'
~89 hours (EPA, the active metabolite)'"`UNIQ--ref-000013D1-QINU`"'
~9 hours (terminal)
~9 hours'"`UNIQ--ref-000014C3-QINU`"'
~9-14 hours'"`UNIQ--ref-00000FD2-QINU`"'
~91 hours
Search
bioavailability:
~25% (oral)'"`UNIQ--ref-00000019-QINU`"' (1)
pregnancy:
Older agent with substantial use experience; observational signals reassuring for first-trimester exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
[[USLegal:Over-the-counter|OTC]] as Bonine and Dramamine Less Drowsy; [[USLegal:Prescription only|Rx-only]] as Antivert (1)
Error in "where" parameter: the string "--" cannot be used within #cargo_query.
There are no results for this report.
Search
Search
Drilldown: Medicines
Add topic
& halflife:
~6 hours'"`UNIQ--ref-00000018-QINU`"' 
generic:
preparations: (Click arrow to add another value)